迈瑞智检实验室解决方案

Search documents
367亿!迈瑞最新财报,40亿研发背后藏着哪些转向信号?
思宇MedTech· 2025-04-29 09:55
正式报名:首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集:2025全球手术机器人大会 2025年4月28日,迈瑞医疗发布2024年年报以及2025年第一季度季报。2024年年度营业收入达到 367.3亿元 ,2025年第一季度营业收入达到 82.4亿 元。 公司预计2025年上下半年的收入将回归到 "前低后高" 的历史常态分布,并呈现出逐季度环比改善的趋势,其中营业收入同比增速将从三季度开始迎来重大 拐点。 # 2024年报数据 迈瑞医疗主要产品覆盖三大 业务 领域, 生命信息与支持、体外诊断以及医学 影像, 叠加"三瑞"智慧生态系统和垂域AI大模型,为医疗机构提供提升整体 诊疗能力的数智化方案。 生命信息与支持 报告期内,公司生命信息与支持业务实现营业收入约 135.57亿元 ,同比 减少11.11%, 其中微创外科业务同比增长超过30%,国际生命信息与支持业务实 现了同比双位数增长。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 36,725,749,548.00 | 34,9 ...
上市公司动态 | 保利发展24年净利降58.6%,迈瑞医疗一季度利润降16.81%,紫光股份、三只松鼠、晶澳科技拟“A+H”
Sou Hu Cai Jing· 2025-04-28 16:55
Group 1: Poly Developments - Poly Developments reported a net profit of 5 billion yuan for 2024, a decrease of 58.6% year-on-year [1] - The company achieved total revenue of 311.67 billion yuan in 2024, down 10% from the previous year [2] - The gross profit margin for settlements was 14%, a decline of 2 percentage points compared to the same period last year [1][2] - The company signed a total area of 17.9661 million square meters, a decrease of 24.7% year-on-year, while sales contracts amounted to 323.029 billion yuan, down 23.5% [2] - The company maintained a cash balance of 134.2 billion yuan at the end of the year, with a net cash flow from operating activities of 6.257 billion yuan [3] Group 2: Mindray Medical - Mindray Medical reported a revenue of 36.726 billion yuan for 2024, an increase of 5.14% year-on-year [5][6] - The net profit attributable to shareholders was 11.668 billion yuan, a slight increase of 0.74% compared to the previous year [5][6] - The company's cash flow from operating activities was not disclosed in the provided data [6] Group 3: Unisplendour - Unisplendour announced plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - The company achieved a revenue of 79.024 billion yuan in 2024, a growth of 2.22% year-on-year [10] - The net profit attributable to shareholders was 1.572 billion yuan, a decrease of 25.23% compared to the previous year [10] Group 4: SF Holding - SF Holding reported a revenue of 69.849 billion yuan for the first quarter, an increase of 6.9% year-on-year [17][18] - The net profit attributable to shareholders was 2.234 billion yuan, reflecting a growth of 16.9% compared to the same period last year [17][18] - The company plans to repurchase shares worth between 500 million and 1 billion yuan [17] Group 5: Qingdao Beer - Qingdao Beer reported a revenue of 10.445 billion yuan for the first quarter, a growth of 2.91% year-on-year [20][21] - The net profit attributable to shareholders was 1.710 billion yuan, an increase of 7.08% compared to the previous year [20][21] Group 6: China State Construction - China State Construction reported a revenue of 555.3 billion yuan for the first quarter, a growth of 1.1% year-on-year [23] - The net profit attributable to shareholders was 15.01 billion yuan, reflecting a growth of 0.6% compared to the same period last year [23] Group 7: WuXi AppTec - WuXi AppTec reported a revenue of 9.655 billion yuan for the first quarter, a growth of 20.96% year-on-year [24] - The net profit attributable to shareholders was 3.672 billion yuan, a significant increase of 89.06% compared to the previous year [24] Group 8: China Nuclear Power - China Nuclear Power reported a revenue of 20.273 billion yuan for the first quarter, a growth of 12.7% year-on-year [25] - The net profit attributable to shareholders was 3.137 billion yuan, reflecting a growth of 2.55% compared to the same period last year [25] Group 9: Haitian Flavoring - Haitian Flavoring reported a revenue of 8.315 billion yuan for the first quarter, a growth of 8.08% year-on-year [26] - The net profit attributable to shareholders was 2.202 billion yuan, an increase of 14.77% compared to the previous year [26] Group 10: Yunnan Baiyao - Yunnan Baiyao reported a revenue of 10.841 billion yuan for the first quarter, a growth of 0.62% year-on-year [27] - The net profit attributable to shareholders was 1.935 billion yuan, reflecting a growth of 13.67% compared to the same period last year [27]
迈瑞医疗(300760) - 一图读懂迈瑞医疗2024年年报及2025年一季报
2025-04-28 14:46
mindray迈瑞 300760.SZ 图读懂 迈瑞医疗2024年年报 & 2025年一季报 生命科技如此亲近 业绩亮点 逆流而上 稳健增长 | 2024年度 | | | | | | --- | --- | --- | --- | --- | | | | | | 单位:亿元 | | 营业收入 | | 303.7 | 349.3 | 367.3 | | 367.3亿元 | | | | | | 同比增长 | | | | | | 5.1%) | | 2022 | 2023 | 2024 | | 归母净利润 | 116.7亿元 | | | | | | | 96.1 | 115.8 116.7 | | | 同比增长 | 剔除财务费用影响后 归母净利润同比增长 | | | | | 0.7% 4.4% ↑ | | 2022 | 2023 | 2024 | | 经营性现金流净额 | | | | | | 124.3亿元 | | 121.4 | 110.6 | 124.3 | | 同比增长 | | | | | | 12.4% ↑ | | 2022 | 2023 | 2024 | | | | | *2024年1月-12月 | | ...